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Volume 59, Number 6S Abstracts 7SCEA alone was performed in 581 symptomatic patients
(32%) and in 1233 asymptomatic patients (68%). Stroke/
death/MI was 4.5% (2.8%/0.5%/1.2%) for symptomatic
patients and 4.0% (2.4%/0.4%/1.1%) for asymptomatic pa-
tients. CEA and coronary artery bypass grafting (CABG)
was performed in 155 patients (98.7% asymptomatic),
S/D/MI of 11.1% (3.9%/5.8/%1.3%). Of 332 patients,
CAS was performed in 119 symptomatic patients (36%)
and in 213 asymptomatic patients (64%), with 255 (77%)
treated as part of a Food and Drug Administration-
approved trial. S/D/MI was 9.2% (4.2%/4.2%/0.8%) for
symptomatic patients and 5.2% (3.3%/1.4%/0.4%) for
asymptomatic patients. Symptomatic CAS patients treated
in a clinical trial (n ¼ 64) had two eventsdS/D/MI of
3.1% (3.1%/0%/0%). Symptomatic patients treated outside
a clinical trial (n ¼ 55) had nine eventsdS/D/MI of
16.4% (5.5%/9%/1/1.8%).
Conclusions: (1). The prospectively collected, inde-
pendently veriﬁed S/D/MI rates for all CEA and CAS
performed within a clinical trial were equivalent to the
CREST results. (2) S/D/MI for CAS in symptomatic
patients was signiﬁcantly higher than CEA (9.2% vs
4.5%; P ¼ .034). (3). S/D/MI for CAS in symptomatic
patients within a clinical trial was equivalent to CEA
(3.1% vs 4.5%; P ¼ .759). Symptomatic CAS patients
who did not qualify for a clinical trial had a ﬁve times
increased risk of S/D/MI of 16.4%. (4) S/D/MI for
CAS in asymptomatic patients was equivalent to CEA
(5.2% vs 4.0%; P ¼ .42). (5). CEA/CABG in asymptom-
atic patients is associated with a three-times increased risk
of S/D/MI compared with patients undergoing CEA for
asymptomatic disease.
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Objectives: Endovascular robotics systems, now
approved for clinical use in the United States and Europe,
are seeing rapid growth in interest. Determining who has
sufﬁcient expertise for safe and effective clinical use remains
elusive. Our aim was to analyze performance on a robotic
platform to determine what deﬁnes an expert user.
Methods: Over three sessions, 20 subjects with a
range of endovascular expertise and endovascular robotic
experience (novices <2 hours to moderate-extensive expe-
rience with >20 hours), performed four tasks on a training
model. All participants completed a 2-hour training session
on the robot by a certiﬁed instructor. Electromagnetic
tracking was used to capture and analyze catheter tip mo-
tion. Motion analysis was based on derivations of speed
and position, including spectral arc length and totalnumber of submovements (inversely proportional to proﬁ-
ciency of motion) and duration of submovements (directly
proportional to proﬁciency).
Results: There was no signiﬁcant difference in
completion times between novices and experienced users.
The experienced users had more efﬁcient motion and per-
formed more consistently. Users with >20 hours per-
formed signiﬁcantly better than those new to the system,
independent of standard endovascular experience (Table).
Conclusions: Expertise in performance of traditional
manual endovascular interventions does not translate to
performance on the endovascular robot. Efﬁciency of cath-
eter movement and consistency of performance may help
identify users who are sufﬁciently trained for safe clinical
use of the system. This work will help identify the learning
curve and speciﬁc movements that translate to expert ro-
botic navigation.
Table. Motion metrics for robotic task performance
Competent Noncompetent PSpectral arc length, mean mm 18.18 28.82 <.0001
Submovements
Mean number per sec 0.415 0.642 <.0001
Mean duration, sec 3.27 1.77 <.0001Author Disclosures: J. Bismuth: Hansen Medical,
consulting fees or other remuneration (payment); C.
Duran: Nothing to disclose; S. Estrada: Nothing to
disclose; M. O’Malley: Nothing to disclose.
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Objectives: Aneurysm related complications can result
in lost of a functioning autogenous arteriovenous ﬁstula
(aAVF). We reviewed our results with aneurysmorrhaphy
to preserve and extend the aAVF use span.
Methods: Over the past 6-year period, we retrospec-
tively reviewed the surgical outcome in patients with an
aAVF who presented with aneurysm-related bleeding,
infection, and/or skin erosion. Of 50 patients who were
identiﬁed, 36 (72%) underwent aneurysmorrhaphy. The
operation involves resecting the redundant aneurysm wall
along with compromised skin and primarily remodeling
the remaining vein to create a conduit 6 to 8mm in diameter.
Results: Thirty-four of 36 (94%) complicated AVFs
were successfully repaired primarily with aneurysmorrha-
phy. Median patient age was 65.5 years (range, 29-88
years). Median AVF age was 61.5 months (range, 12-136
months). Median patient follow-up was 15.5 months
(range, 1-76 months). Seventy-ﬁve percent of patients
had at least 9 months of follow-up, and 25% had at least
28 months. Primary patency was 67% and 57%, assisted pri-
mary patency was 85% and 80%, and secondary patency was
89% and 89% at 1 and 2 years, respectively. Local regional
